Year: 2012
Type: review
Abstract: In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
Institutions: Amsterdam UMC Location Vrije Universiteit Amsterdam, University Hospital of Basel, Charité – Universitätsmedizin Berlin, Karolinska University Hospital, University of Aberdeen, Hospital Universitario HM Sanchinarro, University Hospital Zurich, The Maria Sklodowska-Curie National Research Institute of Oncology, Antwerp University Hospital, Centre Jean Perrin, Azienda Ospedaliero-Universitaria di Modena
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
Funder: Pfizer
OpenAlex ID: W2077409585
